3 Pharmaceuticals stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).
This week, NovaBay Pharmaceuticals, Inc.’s (NBY) ratings are up from a C last week to a B. NovaBay Pharmaceuticals, Inc. develops product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. The company also gets A’s in sales growth and earnings surprise. For more information, get Portfolio Grader’s complete analysis of NBY stock.
Kitov Pharmaceuticals Holdings Ltd. Sponsored ADR (KTOV) is seeing ratings go up from a C last week to a B this week. For more information, get Portfolio Grader’s complete analysis of KTOV stock.
VIVUS, Inc. (VVUS) gets a higher grade this week, advancing from a C last week to a B. VIVUS, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic products for large underserved markets. For more information, get Portfolio Grader’s complete analysis of VVUS stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.